GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gritstone Bio Inc (NAS:GRTS) » Definitions » Piotroski F-Score

Gritstone Bio (Gritstone Bio) Piotroski F-Score : 1 (As of Apr. 29, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Gritstone Bio Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 1 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Gritstone Bio has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Gritstone Bio's Piotroski F-Score or its related term are showing as below:

GRTS' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 1   Max: 4
Current: 1

During the past 8 years, the highest Piotroski F-Score of Gritstone Bio was 4. The lowest was 1. And the median was 1.


Gritstone Bio Piotroski F-Score Historical Data

The historical data trend for Gritstone Bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gritstone Bio Piotroski F-Score Chart

Gritstone Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial 3.00 1.00 4.00 1.00 1.00

Gritstone Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 2.00 2.00 1.00 1.00

Competitive Comparison of Gritstone Bio's Piotroski F-Score

For the Biotechnology subindustry, Gritstone Bio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gritstone Bio's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gritstone Bio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Gritstone Bio's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -33.982 + -35.256 + -38.434 + -30.818 = $-138.49 Mil.
Cash Flow from Operations was -40.09 + -30.963 + -31.087 + -19.508 = $-121.65 Mil.
Revenue was 0.542 + 0.4 + 0.361 + 0.029 = $1.33 Mil.
Gross Profit was 0.542 + 0.4 + 0.361 + 0.029 = $1.33 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(240.754 + 209.952 + 222.623 + 187.217 + 177.769) / 5 = $207.663 Mil.
Total Assets at the begining of this year (Dec22) was $240.75 Mil.
Long-Term Debt & Capital Lease Obligation was $97.87 Mil.
Total Current Assets was $87.44 Mil.
Total Current Liabilities was $27.34 Mil.
Net Income was -28.916 + -29.515 + -29.966 + -31.29 = $-119.69 Mil.

Revenue was 4.745 + 2.761 + 0.436 + 1.327 = $9.27 Mil.
Gross Profit was 4.745 + 2.761 + 0.436 + 1.327 = $9.27 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(278.106 + 243.472 + 213.953 + 205.242 + 240.754) / 5 = $236.3054 Mil.
Total Assets at the begining of last year (Dec21) was $278.11 Mil.
Long-Term Debt & Capital Lease Obligation was $35.02 Mil.
Total Current Assets was $182.88 Mil.
Total Current Liabilities was $34.80 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Gritstone Bio's current Net Income (TTM) was -138.49. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Gritstone Bio's current Cash Flow from Operations (TTM) was -121.65. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-138.49/240.754
=-0.57523447

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-119.687/278.106
=-0.43036468

Gritstone Bio's return on assets of this year was -0.57523447. Gritstone Bio's return on assets of last year was -0.43036468. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Gritstone Bio's current Net Income (TTM) was -138.49. Gritstone Bio's current Cash Flow from Operations (TTM) was -121.65. ==> -121.65 > -138.49 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=97.871/207.663
=0.47129725

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=35.022/236.3054
=0.14820652

Gritstone Bio's gearing of this year was 0.47129725. Gritstone Bio's gearing of last year was 0.14820652. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=87.435/27.339
=3.19817843

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=182.878/34.801
=5.25496394

Gritstone Bio's current ratio of this year was 3.19817843. Gritstone Bio's current ratio of last year was 5.25496394. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Gritstone Bio's number of shares in issue this year was 117.415. Gritstone Bio's number of shares in issue last year was 104.35. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1.332/1.332
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=9.269/9.269
=1

Gritstone Bio's gross margin of this year was 1. Gritstone Bio's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=1.332/240.754
=0.00553262

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=9.269/278.106
=0.03332902

Gritstone Bio's asset turnover of this year was 0.00553262. Gritstone Bio's asset turnover of last year was 0.03332902. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Gritstone Bio has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

Gritstone Bio  (NAS:GRTS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Gritstone Bio Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Gritstone Bio's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Gritstone Bio (Gritstone Bio) Business Description

Traded in Other Exchanges
Address
5959 Horton Street, Suite 300, Emeryville, CA, USA, 94608
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, BiSAb, among others.
Executives
Lawrence Corey director C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Naiyer Rizvi director C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Elaine V Jones director C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Clare Fisher director C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Steve E. Krognes director 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Shefali Agarwal director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Vassiliki Economides officer: See Remarks C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Erin Jones officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
James Cho officer: Chief Accounting Officer C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Raphael Rousseau officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Roman Yelensky officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Thomas Woiwode director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Rahsaan Thompson officer: EVP and General Counsel 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Vijay Yabannavar officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Nicholas Simon director 101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142